Sientra Inc (NASDAQ:SIEN) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totalling 3,120,000 shares, a decline of 17.7% from the August 15th total of 3,790,000 shares. Approximately 7.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,000,000 shares, the days-to-cover ratio is presently 3.1 days.

SIEN traded up $0.05 during trading on Wednesday, reaching $3.70. 10,984 shares of the stock were exchanged, compared to its average volume of 1,225,791. The business’s 50 day moving average price is $3.75 and its two-hundred day moving average price is $3.26. The company has a debt-to-equity ratio of 2.87, a current ratio of 2.85 and a quick ratio of 1.95. The company has a market capitalization of $183.64 million, a price-to-earnings ratio of -1.73 and a beta of 1.52. Sientra has a 1 year low of $1.00 and a 1 year high of $9.71.

Sientra (NASDAQ:SIEN) last issued its quarterly earnings data on Monday, August 10th. The medical instruments supplier reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($0.23). Sientra had a negative net margin of 140.76% and a negative return on equity of 130.33%. The company had revenue of $12.45 million during the quarter, compared to analysts’ expectations of $8.87 million. On average, analysts anticipate that Sientra will post -1.6 EPS for the current year.

SIEN has been the topic of a number of analyst reports. Maxim Group restated a “buy” rating and issued a $8.00 price target on shares of Sientra in a research note on Wednesday, August 12th. SVB Leerink lifted their price target on Sientra from $5.30 to $6.00 and gave the company an “outperform” rating in a research note on Tuesday, August 11th. Canaccord Genuity reiterated a “buy” rating and set a $6.00 target price on shares of Sientra in a research report on Friday, August 14th. Finally, Zacks Investment Research downgraded Sientra from a “buy” rating to a “hold” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $6.42.

Several large investors have recently modified their holdings of SIEN. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Sientra in the first quarter valued at $30,000. Bank of Montreal Can purchased a new stake in shares of Sientra in the second quarter valued at $39,000. Principal Financial Group Inc. purchased a new stake in shares of Sientra in the second quarter valued at $41,000. Lighthouse Financial Advisors Inc. lifted its position in shares of Sientra by 87.5% in the first quarter. Lighthouse Financial Advisors Inc. now owns 22,500 shares of the medical instruments supplier’s stock valued at $44,000 after acquiring an additional 10,500 shares in the last quarter. Finally, Wedbush Securities Inc. purchased a new stake in shares of Sientra in the second quarter valued at $45,000. Institutional investors and hedge funds own 76.86% of the company’s stock.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names.

Further Reading: The mechanics of the bid-ask spread in trading

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with's FREE daily email newsletter.